Allakos Inc. ALLK
We take great care to ensure that the data presented and summarized in this overview for Allakos Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALLK
View all-
Bvf Inc San Francisco, CA16.6MShares$4.8 Million0.75% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$1.78 Million0.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.7MShares$1.65 Million0.3% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.63MShares$1.05 Million1.7% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.59MShares$1.04 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.43MShares$994,1600.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.02MShares$874,3780.29% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.96MShares$857,2710.7% of portfolio
-
Logos Global Management LP San Francisco, CA2.9MShares$841,0000.46% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY2.55MShares$738,3824.86% of portfolio
Latest Institutional Activity in ALLK
Top Purchases
Top Sells
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Insider Transactions at ALLK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,138
-6.89%
|
$13,138
$1.1 P/Share
|
|
Dec 06
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
21,116
-3.81%
|
$21,116
$1.1 P/Share
|
|
Dec 05
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,466
-4.05%
|
$32,466
$1.1 P/Share
|
|
Dec 04
2024
|
Chin Hyok Lee Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,634
-3.72%
|
$10,634
$1.13 P/Share
|
|
Sep 11
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,311
-4.45%
|
$0
$0.58 P/Share
|
|
Sep 09
2024
|
Chin Hyok Lee Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
45,320
-13.69%
|
$0
$0.65 P/Share
|
|
Sep 06
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,665
-6.69%
|
$0
$0.65 P/Share
|
|
Sep 06
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
21,961
-3.81%
|
$0
$0.65 P/Share
|
|
Jun 28
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
87,064
-29.87%
|
$87,064
$1.01 P/Share
|
|
Jun 07
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
24,749
-4.14%
|
$24,749
$1.12 P/Share
|
|
Jun 06
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,525
-4.29%
|
$37,525
$1.14 P/Share
|
|
Jun 04
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,565
-4.76%
|
$14,565
$1.19 P/Share
|
|
Mar 06
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,142
-9.5%
|
$32,142
$1.35 P/Share
|
|
Mar 05
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
47,392
-7.35%
|
$47,392
$1.44 P/Share
|
|
Mar 04
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
70,910
-7.51%
|
$70,910
$1.48 P/Share
|
|
Dec 04
2023
|
Craig A. Paterson Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,992
-2.12%
|
$13,984
$2.5 P/Share
|
|
Dec 04
2023
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
16,054
-2.44%
|
$32,108
$2.5 P/Share
|
|
Dec 04
2023
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,753
-2.56%
|
$49,506
$2.5 P/Share
|
|
Dec 04
2023
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,380
-2.42%
|
$16,760
$2.5 P/Share
|
|
Sep 05
2023
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,096
-2.83%
|
$84,288
$3.01 P/Share
|
Last 12 Months Summary
| Payment of exercise price or tax liability | 423K shares |
|---|---|
| Open market or private sale | 87.1K shares |